Frequently Asked Questions
In a world of binary events covering hundreds of drugs there are sure to be some questions.
BioPharmCatalyst does not issue recommendations regarding the purchase and selling of stocks.
Small-mid cap biotech companies listed on AMEX and NASDAQ. Large cap companies are not covered. OTC companies are also not covered.
SEC Filings and press releases.
The short ratio is the number of shares sold short divided by the average daily volume (ADV). It shows approximately how many days it will take short-sellers to cover their positions. The higher the ratio, the longer it would take to buy back the short shares.
While the value of short interest (shares sold short) is always known the ADV will differ according to the time period. For example, the ADV over 10 days will be different to the ADV over 30 days, 6 months etc.
Consequently, the short ratio value will differ according to the ADV value that is used.
No. The FDA Calendar is run independently of the FDA. There is no affiliation between the FDA and BioPharmCatalyst.
Yes. Please visit the Historical Catalyst Database.
BioPharmCatalyst focuses on companies listed on AMEX/NASDAQ.
A company must have a drug in Phase 2 or 3 development or have an upcoming PDUFA date to be listed on BioPharmCatalyst.
Over time, however, Phase 1 catalysts of small cap companies will be added.
No. Financial data (e.g. price and volume) are updated once every 20 minutes and that data is already 15 minutes delayed from our feed provider so the data you see will be delayed in total 15-35 minutes.
The six stages represent the different stages of drug development, from Phase 1 (Stage 1) to the final stage when the FDA makes their decision whether to approve the drug or not (Stage 6). This is not an official scale, rather just one used by BioPharmCatalyst.
1) Phase 1, Phase 1b, Phase 1/2
2) Phase 2, Phase 2b
3) Phase 3
4) NDA filing
5) PDUFA
6) Approved/CRL
Members are locked into the price they signed up to for their current membership.
For example, a member signs up for $17, this price will remain fixed until they cancel their membership. If a member cancels their membership and rejoins the service at a later date they will pay the new rate at the time they rejoin.
An API or other means to load data to Excel is currently is not available.
Users are reminded that scraping on data is not permitted as per the Terms of Use.
"You must not copy, adapt, reproduce, display, frame, mirror, scrape, data-mine, extract, harvest, distribute, transmit, republish, modify or revise the contents of this website in whole or in part in any form or by any means"
SMALL CAP - Biotech stocks with key binary events/catalysts - FDA Approval/PDUFA dates, Advisory Committee and Phase 2 & 3 trial data releases dates are noted in the FDA Calendar. If a trial is ongoing but the company has not yet provided an upcoming catalyst date, the drug concerned will ONLY be listed in the Drug Pipeline Database and will not be listed in the FDA Calendar until a catalyst date is provided. Phase 1 catalysts for small-cap companies only are listed.
LARGE CAP - generally only Phase 3 catalysts noted in company presentations and/or earnings releases are shown. Earlier stage drugs (Phase 2) are included if the company provides catalyst date updates for the trial in earnings releases/presentations.
Only NASDAQ and NYSE stocks are covered. Stocks listed on PINK/OTC exchanges are not covered.